Health Care·Biotechnology·$8.6B
Vaxcyte Inc (PCVX) is a biotechnology company focused on developing vaccines to prevent infectious diseases. With a market cap of $9 billion, the company operates in the health care sector, which is increasingly important as global health challenges evolve.
EPS
Earnings per share (EPS) is a critical measure of the company's profitability and financial health.
Revenue
Although no revenue is expected this quarter, any updates on future revenue potential could impact investor sentiment.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
0Q
EPS Beat Rate
25%
Avg EPS Surprise
-38.22%
Avg Stock Reaction
-1.00%
In Q4 2025, Vaxcyte reported an EPS of $-5.63, significantly missing analyst expectations. The stock reacted positively, gaining 1.81% the next day despite the disappointing results.
Management Promises & Guidance
Analysts expect continued losses for Vaxcyte, with a consensus EPS of $-1.77. Investors are likely looking for any signs of progress in vaccine development or future revenue potential.
Bull Case
If Vaxcyte can demonstrate progress in its vaccine pipeline or provide guidance on future revenue, it could lead to a positive market reaction.
Bear Case
Conversely, if the company fails to provide any updates on its product pipeline or if losses widen, investor confidence may decline.
EPS
$-1.77Earnings per share (EPS) is a critical measure of the company's profitability and financial health.
Revenue
$0MAlthough no revenue is expected this quarter, any updates on future revenue potential could impact investor sentiment.
The print will turn on these two things.
Q1
What specific updates can management provide on the vaccine pipeline?
Investors will be keenly interested in any advancements or setbacks in the vaccine development process, as this could significantly impact future revenue potential.
Q2
Will there be any guidance on expected losses or potential revenue in the upcoming quarters?
Clear guidance on financial expectations can help set investor sentiment and expectations for the company's performance.
Why consensus could be wrong
The Street may be underestimating the potential for Vaxcyte to provide updates on its vaccine pipeline that could lead to future revenue.
Supporting Evidence
The recent positive stock reaction despite a large EPS miss suggests some investor optimism.
Historical data shows that the stock has reacted positively in the past despite disappointing earnings.
Key Risk
If management provides strong updates on vaccine development, it could significantly shift investor sentiment.
Pre-commit to what would confirm each case.
The market is debating the company's ability to turn around its financial performance and provide clarity on its vaccine pipeline.
Bull Confirmed If
Any indication of progress in vaccine development or a narrower loss than expected could confirm a bullish outlook.
Bear Confirmed If
A wider loss than the consensus EPS of $-1.77 would confirm a bearish outlook.
Implied Move
±N/A
There is no options market data available for Vaxcyte at this time.
Cross-company pattern from 30 similar setups.
Prior-quarter miss setup in Health Care
n=30Fade rate: 10 of 27 (37%)
This setup has occurred 30 times across Health Care in the last 2 years. 17 of 27 (63%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 6.7%, with a raw directional average of +3.7% (modestly positive historical bias).
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Vaxcyte beats expectations and raises guidance, history suggests a modest positive reaction, potentially around +1.81%.
In-Line / Cautious
If results are in line with expectations but lack strong guidance, the stock may see muted movement as investors reassess their outlook.
Miss
A miss on EPS could lead to a decline, with history suggesting an average drop of around -1.32%.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PARAMOUNT SKYDANCE C Class B
May 4, 2026